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Background: Myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal myeloid neoplasms. Allogeneic stem cell 
transplantation (allo-SCT) remains the curative method for MDS treatment. Little is known about the monitoring of minimal residual 
disease (MRD) in patients with MDS after allo-SCT.  Aim:   We aimed to evaluate the significance of leukemia-associated immunophenotypes 
(LAIPs) identified in acute myeloid leukemia (AML) for MRD monitoring in patients with MDS after allo-SCT. Material and methods: Seven 
males and 4 females with a median age of 55 years were included. The diagnosis of MDS was established according to 2016 World Health 
Organization (WHO) criteria. The significance of eight LAIPs in bone marrow samples using multiparameter flow cytometry (MFC) was 
evaluated for MRD. Results: Eight patients were positive for several LAIPs before allo-SCT. The identified LAIPs included the presence of 
aberrant lymphoid antigens on myeloblasts and lack of CD33 expression on myeloblasts. All studied MDS patients were negative for 
LAIPs at Day +30 after the procedure. This was followed by full-donor chimerism in all cases. The Ogata score after allo-SCT decreased 
in all patients in whom it was indicative for MDS before allo-SCT. Conclusions: MFC could be useful in monitoring MRD in MDS patients 
after allo-SCT. Further studies in this field are needed.
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Introduction
Myelodysplastic syndromes (MDSs) constitute a heterogeneous 
group of clonal myeloid neoplasms characterized by the presence 
of dysplastic cells within the bone marrow (BM) [1, 2]. It results in 
abnormal hematopoiesis with mono-, bi-, or multilineage cytopenia in 
peripheral blood (PB) [1]. The diagnosis of MDS requires evaluation 
of BM aspirate/biopsy, including the assessment of blast proportion 
and the presence of dysplastic features [3]. Clinical heterogeneity 
among MDS cases requires the establishment of an individual’s risk 
category, which determines the prognosis and the choice of therapy. 
The International Prognostic Scoring System (IPSS) and the Revised 
International Prognostic Scoring System (IPSS-R) are the most widely 
used tools for a patient’s risk assessment. The choice of therapy 
depends on IPSS-related risk category [3]. First-line treatment for 
lower-risk patients (low and intermediate-1 IPSS categories) includes 
erythropoietin, granulocyte-colony-stimulating factor, androgens, 
transfusions, iron chelation drugs, and supportive care. Patients 
with 5q deletion usually benefit from lenalidomide [4, 5]. Higher-risk 
patients (intermediate-2 and high-risk according to IPSS) are usually 
treated with hypomethylating agents (azacitidine and decitabine), but 
the only curative therapy for eligible patients is allogeneic stem cell 
transplantation (allo-SCT) [6].
The development of therapy entails the need to improve existing 
and find new monitoring methods for patients with MDS. The role of 
multiparameter flow cytometry (MFC) in the diagnosis, monitoring, and 
prediction of outcome in patients with acute myeloid leukemia (AML) is 
well established [7–10]. Immunophenotypic patterns of maturation in 
hematopoietic lineages are well understood [11, 12]. Minimal residual 
disease (MRD) is a sensitive method useful in the assessment of 
pathological cells elusive in cytomorphological evaluation. Assessment 
of MRD by MFC is based on identifying aberrant clones characterized 
by specific cell–antigen combinations (immunophenotype) [13]. Several 
studies investigating the use of MFC in the diagnosis, monitoring, and 
prediction of outcome in MDS have been conducted [14, 15, 16]. The 
Ogata score has also been designed as a simple scoring system useful 
in screening for MDS [17].
Use of MFC in clinical practice for MDS may address technical and 
interpretational difficulties [18, 19]. There are single reports on MRD 
monitoring in MDS patients after allo-SCT based on evaluation of 
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posttransplant chimerism and mutational status [20, 21]. Data on 
MFC use for MRD monitoring after allo-SCT in this group of patients 
are sparse [22, 23].
The aim of the study was to evaluate the utility of leukemia-associated 
immunophenotypes (LAIPs) identified in AML for MRD monitoring in 
patients with MDS treated with allo-SCT.
Patients
The preliminary analysis involved 11 patients who underwent 
allo-SCT at the Department of Hematology and Bone Marrow 
Transplantation, Silesian Medical University Poland, between March 
2017 and July 2018. We evaluated seven males and four females 
aged between 40 and 66 years (median age: 55 years). All patients 
signed informed consent before entering the study. The diagnosis of 
MDS was established according to the revised 2016 World Health 
Organization (WHO) classification criteria [1]. The disease-risk 
category was assessed by IPSS-R. Ten patients were treated with 
one (n = 7), two (n = 3), or three (n = 1) lines of therapy. The therapy 
was based on corticosteroids and androgens (n = 3), azacitidine 
(n = 3), and intensive chemotherapy protocols for AML (n = 6). 
Patients’ characteristics are listed in table I.
The choice of conditioning regimen was dependent on patient’s age, 
performance status, and comorbidities. Transplantation details are 
included in table II.
Table II. Transplantation procedure details
Number (%) 11 (100)
Type of donor 
    Matched related, n (%) 1 (9)
    Matched unrelated, n (%) 7 (64)
    Mismatched unrelated, n (%)  3 (27)
Source of hematopoietic stem cells     
    Peripheral blood, n (%) 11 (100)
Conditioning regimen 
 Myeloablative conditioning, n (%) 6 (54)
     BuCy, n (%) 5 (45)
     BuFlu, n (%) 1 (9)
 Reduced intensity conditioning, n (%) 5 (45)
     TreoFlu, n (%) 5 (45)
GvHD prophylaxis
    CsA + Mtx, n (%) 10 (91)
    CsA + MM, n (%) 1 (9)
BuCy – busulfan plus cyclophosphamide; BuFlu – busulfan plus fludarabine; 
TreoFlu – treosulfan plus fludarabine; GvHD – graft-versus-host disease;  CsA 
+ Mtx – cyclosporine plus methotrexate; CsA + MM – cyclosporine plus myco-
phenolate mofetil  
Material and methods
MRD was evaluated by MFC using BM samples collected in 
ethylenediaminetetraacetic acid (EDTA) tubes after obtaining 
informed consent from 11 patients with MDS [at two time points 
– before and at Day +30 after allo-HSCT (n = 11)]. Staining with 
monoclonal antibodies (moAb) was made after erythrocyte lysis 
procedure. The evaluation or MRD was done immediately after moAb 
staining. The analysis was performed on eight-color flow cytometer 
FACS Canto II with FACS Diva program (Becton-Dickinson, USA). 
The analysis was performed according to European LeukemiaNet 
recommendations on minimum 500,000 CD45+ cells [24]. All 
moAbs and isotype-matched negative control were produced by 
Becton-Dickinson (San Jose, USA). The percentage of CD34+ 
myeloblasts, B-cell precursors among CD34+ cells, and lymphocytes/
Table I. Patient and disease characteristics 
Number of analyzed patients (%) 11 (100)
Gender 
     Male (%) 7(64)
     Female (%) 4 (36)
Median age at diagnosis, years (range) 55 (39–65)
Median age at allo-SCT, years (range) 55 (40–66)
Diagnosis, number (%)    
    MDS-SLD 1 (9)
    MDS-MLD 2 (18)
    MDS-EB-1 1 (9)
    MDS-EB-2 7 (64)
Disease risk category, number (%)
    IPSS-R
      Very low 1 (9)
      Low 1 (9)
      Intermediate 4 (36)
      High 3 (27)
      Very high 2 (18)
Disease status at allo-SCT, number (%)
    MDS-SLD 1 (9)
    MDS-MLD 4 (36)
    MDS-EB-1 2 (18)
    MDS-EB-2 4 (36)
Transfusion dependency, number (%) 10 (90)
Cytopenia before allo-SCT, number (%) 9 (81)
    1-lineage 2 (18)
    2-lineage 5 (45)
    3-lineage 2 (18)
Blast percentage in PB before transplantation, median 
(range)
0 (0–7)
Blast percentage in BM before transplantation, median 
(range)
5.5 (0–16)
MDS-SLD – myelodysplastic syndrome with single lineage dysplasia; MDS-
MLD – myelodysplastic syndrome with multilineage dysplasia; MDS-EB – 
myelodysplastic syndrome with excess; IPSS-R – Revised International 
Prognostic Scoring Systeml; allo-SCT – allogeneic stem cell transplantation; 
PB – peripheral blood; BM – bone marrow
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myeloblasts CD45+ ratio, as well as granulocytes-to-lymphocytes 
side scatter (SSC) peak ratio, was assessed to evaluate the Ogata 
score for each patient before allo-HSCT [25].
The antigens aberrantly expressed on myeloblasts (CD2, CD7, 
CD56, CD13+CD33-) were identified within CD45dim SSClow/int CD34+ 
and CD45dim SSClow/int CD34-CD117+cell compartments [18]. The 
expression of aberrant antigens on myeloid progenitors >30% was 
considered as a positive result. The myeloblast gating strategy is 
shown in figure 1.
The MRD analysis was conducted by evaluation of expression 
of selected aberrant lymphoid antigens (CD2, CD7, CD22, and 
CD56) on CD34+ myeloblasts and lack of expression of CD33 on 
CD13+CD34+ myeloblasts, which were found in AML [9, 24, 25]. All 
the analyzed aberrant immunophenotypes, i.e., LAIPs, are highly 
specific for myeloblast identification: their expression in healthy or 
regenerative BM is <0.1% [25]. MRD results >0.1% (>1/1,000 total 
BM cells) are considered positive [9]. Detected immunophenotypes 
used for MRD evaluation are shown in table III.
The gating strategy was based on identifying CD34+ cells within 
CD45dim SSClow/int and then distinguishing the percentage of 
CD13+CD7+, CD13+CD33-, CD13+CD22+, CD33+CD22+, 
CD13+CD56+, CD33+CD56+, CD13+CD2+, and CD33+CD2+ 
in this population [9]. BM and PB smears were prepared for 
cytomorphological evaluation by the May-Grünwald-Giemsa staining 
and counted for 200 nuclear cells. The evaluation of chimerism was 
based on deoxyribonucleic acid (DNA) analysis by polymerase chain 
reaction (PCR) by the short tandem repeat method.











Aberrant immunophenotypes on BM myeloblasts were identified in 
eight cases. The final three patients did not reveal any LAIPs. The 
immunophenotypes were characterized by the expression of lymphoid 
Fig. 1. Gating strategy of MFC aberrancies in myeloid progenitor cells
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lineage-specific antigens, viz., CD7 (n = 3) and CD2 (n = 1), or the 
presence of CD13+CD33 coexpression (n = 6). Eight patients were 
MRD-positive before allo-SCT (median of MRD was 0.226; range: 
0.12–4.79). All of them were MRD-negative at Day +30 after allo-
SCT (median: 0.005; range: 0.001–0.079), which corresponds with 
full-donor chimerism at the second time point. The Ogata score was 
calculated for all patients before and at Day +30 after allo-SCT. This 
score was designed as a simple scoring system useful in screening 
for MDS. It evaluates the percentage of myeloblasts within all marrow 
cells, percentage of B-precursors within the CD34+ cell subset, ratio 
of CD45+ lymphocytes to CD45+ myeloblasts, and granulocyte-to-
lymphocyte SSC ratio. Results ≥2 indicate a diagnosis of MDS [17]. 
All studied cases indicated as MDS by the score before allo-SCT 
showed decreased value at Day +30 after transplantation. The study 
results are shown in table IV.
Discussion
Myeloablative allo-SCT procedure is applicable for patients without 
severe comorbidities. Thus, the development of reduced-intensity 
conditioning allo-SCT (RIC allo-SCT), which is characterized by 
less toxicity, is a more suitable option for patients with MDS who are 
usually in advanced age [26]. Relapse after allo-SCT is considered 
to be the major cause of death in this group of patients. This 
indicates the importance of MRD monitoring in posttransplant care, 
which helps to predict the relapse and decide on further therapeutic 
approaches [22, 27]. Single studies showing the utility of mutational 
status monitoring of Wilms’ Tumor 1 gene (WT1) after allo-SCT in 
patients with MDS have been conducted [28, 29]. These data are 
limited and the method is not widely used. Another study on a large 
population of patients with MDS has revealed that almost 80% of 

































































































































































2 F / 46 MDS-MLD No immunophenotype detected – – 2 1 100














5 F / 60 MDS-MLD No immunophenotype detected – – 3 0 100
6 M / 44 MDS-MLD No immunophenotype detected – – 1 1 99












































MDS-SLD – myelodysplastic syndrome with single lineage dysplasia; MDS-MLD – myelodysplastic syndrome with multilineage dysplasia; MDS-EB – myelodys-
plastic syndrome with excess; allo-SCT – allogeneic stem cell transplantation; MRD – minimal residual disease
A c t a  H a e m a t o l o g i c a  P o l o n i c a
92
patients have mutation in at least one of the 111 analyzed genes 
[30]. These data are promising; however, analysis of such a large 
number of genes in clinical practice raises difficulties. Monitoring 
of MRD with cytogenetics is also challenging since only 50% of 
patients reveal cytogenetic abnormalities [31]. MFC seems to give 
the opportunity to overcome these limitations. This precise method 
allows obtaining quantitative results in a relatively short time at lower 
costs [32]. The role of MFC in MRD monitoring in acute leukemias is 
well established, and the evaluation of immunophenotype is possible 
in > 90% patients [33]. The most widely used MFC approach of 
MRD evaluation is based on the identification of LAIPs. This method 
allows for the identification of expression of abnormal antigens on 
blasts, which are not detected or extremely rare (<0.1%) in healthy 
or regenerative BM.
The aberrancies may manifest as expression of different-lineage-
specific antigens, asynchronous expression, and overexpression 
or loss of lineage-specific antigens [9, 34, 35]. Immunophenotypes 
identified in our study reveal the presence of CD2 and CD7, which 
are typical for T-lineage and are aberrantly expressed in cases with 
myelodysplasia or AML [19, 35, 36]. Data indicate that expression 
of CD7 on myeloblasts is frequently seen in cases of AML with 
Fms-like tyrosine kinase-3 internal tandem duplication (FLT3/ITD) and 
– through it – is associated with worse outcome [37]. The prognostic 
significance of CD7 expression on myeloblasts in MDS has also been 
evaluated; however, the results are divergent [38, 39]. Another study 
has shown that increase in CD7 and decrease in CD15 on CD34+ 
myeloblasts are seen in more advanced stages of the disease [40]. 
In our observation, CD7 is found in patients with different disease 
stages – MDS-MLD, MDS-EB-1, and MDS-EB-2. We have also 
found two immunophenotypes with expression of CD56, which is the 
aberrant feature in CD34+ cells. This aberrancy is also identified in 
cases of myelodysplasia [19]. Expression of this antigen on blasts is 
supposed to be associated with worse response to growth factors in 
lower-risk MDS [41]. CD56 is an antigen used for LAIP evaluation in 
patients with AML and seems to be associated with poor prognosis 
in certain AML subgroups [42, 43]. The most frequently seen 
immunophenotype identified in our analysis includes CD13+CD33- 
antigen combination, which can be found in progenitors, neutrophils, 
and monocytes in MDS and has been identified in LAIPs in 
AML [18, 19, 25, 44].
Several studies have assessed the impact of MRD status on the 
outcome in patients with acute leukemias treated with allo-SCT. It 
has been shown that patients transplanted for acute lymphocytic 
leukemia (ALL) who had positive MRD at transplant had higher 
relapse rate and shorter progression-free survival [45]. Higher 
incidence of relapse and death after allo-SCT is also seen in 
MRD-positive patients transplanted in complete remission of AML 
[46]. Available data suggest that patients with MDS and positive 
MRD at the time of transplantation are characterized by worse 
posttransplant outcome; however, it differs depending on the type of 
applied conditioning regimen [22]. All of our patients with identified 
immunophenotypes were MRD positive at the time of allo-SCT; one 
of them died because of acute graft versus host disease (aGvHD) 
and one because of chronic graft versus host disease (cGvHD). 
One patient relapsed early after allo-SCT; however, none of the 
identified immunophenotypes before transplantation was detected at 
the relapse (data not shown). Limited data of monitoring MRD after 
allo-SCT in patients with MDS suggest that the outcome of patients is 
better when the MRD value is lower at Day +100 after allo-SCT [23]. 
All of our patients with identified immunophenotypes had negative 
MRD at Day +30 after allo-SCT, which corresponded with 100% 
chimerism detected in most of cases.
We also evaluated the Ogata score before and at Day +30 
after allo-SCT. Several studies analyzed the score’s utility as a 
diagnostic tool for MDS; however, they demonstrated its limitation 
[17, 19, 47]. There are no data of application of this score after 
allo-SCT. In eight of our cases, the results obtained before allo-
SCT indicated MDS diagnosis (the value was ≥2). All of these 
eight results decreased when evaluated at Day +30 after allo-SCT. 
This may be associated with eradication of the clonal population 
of MDS in the BM, which seems to be confirmed by full-donor 
chimerism in these cases.
Conclusions
In our opinion, MFC may be a useful tool for evaluation of LAIPs 
and monitoring of MRD in patients with MDS qualified to allo-SCT. 
We would like to emphasize that this study is a pilot project in this 
field. The obtained results suggest the need for further observation 
and assessment of MRD at subsequent time points after allo-SCT 
in larger populations. Further studies on standardization of MFC 
application in MDS are needed.
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